Can discontinuation of oxybutynin two weeks ago cause my eyelid twitching?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discontinuing Oxybutynin Is Unlikely to Cause Your Eyelid Twitching

Oxybutynin discontinuation two weeks ago is not a recognized cause of eyelid twitching, and your symptom is most likely unrelated to stopping this medication.

Why Oxybutynin Is Not the Culprit

Anticholinergic Effects Resolve Rapidly After Discontinuation

  • Oxybutynin's anticholinergic side effects (dry mouth, constipation, blurred vision) occur during active treatment, not after stopping the medication 1, 2.
  • These adverse effects lead to treatment discontinuation in up to 25% of patients while taking the drug, not after cessation 2, 3.
  • The drug undergoes extensive first-pass metabolism with an active metabolite (N-desethyloxybutynin), but these compounds clear from the system within days, not weeks 2, 4.

No Documented Withdrawal Syndrome

  • There is no evidence in the medical literature of a withdrawal syndrome from oxybutynin that includes eyelid twitching or other neuromuscular symptoms 1, 5, 6.
  • Anticholinergic medications do not typically cause rebound cholinergic effects that would manifest as muscle twitching after discontinuation.

What Is Actually Causing Your Eyelid Twitching

Benign Eyelid Myokymia (Most Likely)

  • Chronic isolated eyelid myokymia is a benign, self-limited condition that typically begins as intermittent unilateral eyelid spasms occurring weekly or biweekly, then progresses to daily spasms over several months 7.
  • This condition affects women more than men (3:1 ratio) and tends to develop more frequently in cold weather (61% of cases) 8.
  • In 86.7% of cases, neuroimaging shows no abnormalities, and the condition does not progress to other neurologic diseases 7.

Electrophysiological Findings

  • About half of chronic eyelid twitching cases demonstrate delayed or absent R2 response in blink reflex testing 8.
  • Approximately 45.8% of cases show prolonged facial nerve latency, suggesting minor facial nerve conduction defects 8.

Clinical Pitfalls to Avoid

Do Not Attribute Benign Symptoms to Recent Medication Changes

  • The temporal association between stopping oxybutynin and developing eyelid twitching is coincidental, not causal.
  • Eyelid myokymia typically has an insidious onset over months, not an acute onset related to medication changes 7.

Red Flags That Would Require Further Evaluation

  • If the twitching progresses to involve other facial muscles beyond the eyelid, consider hemifacial spasm (occurred in only 1 of 15 patients with chronic eyelid myokymia) 7.
  • If accompanied by variable ptosis, diplopia, or strabismus that worsens with fatigue, consider myasthenia gravis 9.
  • Pupillary involvement should prompt evaluation for third nerve palsy rather than benign myokymia 9.

Management Approach

Expectant Management

  • Four out of 15 patients (26.7%) with chronic eyelid myokymia experienced spontaneous resolution without treatment 7.
  • Reassurance about the benign nature of the condition is appropriate.

Treatment Options If Bothersome

  • Eight of 11 patients who did not experience spontaneous resolution reported improvement with botulinum toxin injections administered at regular intervals 7.
  • This represents the most effective treatment for persistent, bothersome eyelid myokymia.

No Need for Extensive Workup

  • Neuroimaging is typically negative (86.7% of cases) and may not be necessary unless other concerning neurologic signs develop 7.

References

Guideline

Anticholinergic Side Effects and Treatment Discontinuation of Oxybutynin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Oxybutynin and the overactive bladder.

World journal of urology, 2001

Research

Transdermal oxybutynin: a new treatment for overactive bladder.

Expert opinion on pharmacotherapy, 2003

Guideline

Oxybutynin vs. Flavoxate for Overactive Bladder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Urinary Incontinence in Young Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Chronic myokymia limited to the eyelid is a benign condition.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2004

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the recommended treatment for overactive bladder using Oxybutynin?
Is oxybutynin (antimuscarinic) a suitable first-line treatment for a patient with bladder overdistension?
Should the oxybutynin (antimuscarinic) dose be increased in an 86-year-old female (YOF) with overactive bladder, currently taking 2.5mg/day, who still experiences symptoms?
Can oxybutynin be used for short-term management of overactive bladder?
What is Oxybutynin, its indications, and potential side effects in patients, particularly older adults or those with benign prostatic hyperplasia (BPH), glaucoma, or gastrointestinal disorders?
How should I manage a three‑day‑old eyelid myokymia in an otherwise healthy individual?
In a 44‑year‑old patient with iron‑deficiency anemia who has just received two units of packed red blood cells and now has a hemoglobin of 8.2 g/dL, when should intravenous iron monoferric (iron isomaltoside 1000) be initiated?
What are the core symptoms of attention-deficit/hyperactivity disorder?
How should I manage hyperprolactinemia caused by risperidone in a child?
In a 50‑year‑old woman with systemic lupus erythematosus and Lambert‑Eaton myasthenic syndrome who has low factor VIII activity, markedly reduced von Willebrand factor antigen (VWF:Ag) and activity (VWF:RCo), very low ristocetin cofactor, normal multimer distribution, low immunoglobulin A (IgA) and immunoglobulin M (IgM), and elevated polyclonal immunoglobulin G (IgG), what is the most likely diagnosis and how should it be managed?
Is chromium supplementation appropriate for treating insulin resistance in critically ill patients in the intensive care unit?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.